Dyne Therapeutics Inc (DYN)

In December 2025, Dyne Therapeutics announced positive topline results from the Phase 1/2 DELIVER trial of Z-Rostudirsen in DMD, followed by announcements of a public offering of common stock, which influenced stock movement. In July 2025, the company closed a public offering of common stock. In June 2025, Dyne Therapeutics announced the pricing of a $200.0 million public offering of common stock and secured up to $275 million in debt financing. The all-time high closing stock price for Dyne Therapeutics was $47.04 on August 21, 2024. Shares of DYN fell 53% to an intraday low of $6.40 on October 30, 2023, but subsequently more than tripled on positive news from a data readout in January 2024.

Dyne Therapeutics' products and services do not exhibit typical demand seasonality. The demand for its product candidates would be driven by the prevalence of the specific rare diseases they target rather than seasonal fluctuations. The company's business model is high-cost, high-risk, but potentially high-reward, with future pricing expected to follow a specialty pharmaceutical model targeting ultra-orphan diseases.

Dyne Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for genetically driven neuromuscular diseases, utilizing its proprietary FORCE™ platform to deliver therapeutic oligonucleotides to muscle tissue and the central nervous system. Its product candidates include Zeleciment basivarsen for Myotonic Dystrophy Type 1 (DM1), Zeleciment rostudirsen for Duchenne Muscular Dystrophy (DMD), DYNE-302 for Facioscapulohumeral Muscular Dystrophy (FSHD), and DYNE-401 for Pompe disease. The company plans to expand its portfolio to include other rare skeletal muscle, cardiac, and metabolic muscle diseases.

Dyne Therapeutics, Inc. is headquartered in Waltham, Massachusetts, United States. Its clinical trials indicate a global reach for its research and development activities.

Dyne Therapeutics' brand reputation has been influenced by its clinical trial progress and financial activities. Positive clinical data for DYNE-101 and DYNE-251 in 2024 validated its targeted delivery approach. The FDA granting Breakthrough Therapy Designation for DYNE-101 and DYNE-251 signaled regulatory confidence. Public offerings of common stock can lead to stock price volatility. Analysts remain optimistic about Dyne's long-term prospects, and the high percentage of institutional ownership suggests strong investor confidence.

Dyne Therapeutics, Inc. has high institutional ownership, with over 90% of the company held by large funds and asset managers. As of January 9, 2026, there are 411 institutional owners holding a total of 167,643,026 shares. Major institutional owners include Janus Henderson Group Plc, Vanguard Group Inc, BlackRock, Inc., Atlas Venture Life Science Advisors, LLC, Fmr Llc, State Street Corp, TCG Crossover Management, LLC, and Adage Capital Partners Gp, L.l.c. Atlas Venture Fund XI LP is the largest individual shareholder.